TriSalus生命科学公司(TriSalus Life Sciences Inc.)近日宣布,其核心产品Trinav® Advance已获得美国食品药品监督管理局(FDA)的上市许可。这一里程碑式的进展,将显著增强该公司在肝脏栓塞治疗领域所构建的全面压力介导药物递送(Pedd™)产品组合。
TriSalus生命科学公司(TriSalus Life Sciences Inc.)近日宣布,其核心产品Trinav® Advance已获得美国食品药品监督管理局(FDA)的上市许可。这一里程碑式的进展,将显著增强该公司在肝脏栓塞治疗领域所构建的全面压力介导药物递送(Pedd™)产品组合。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.